David Rodman sells 192,715 shares at Mineralys
Mineralys Therapeutics insider transactions: David Rodman reported multiple sales of common stock, including a sale of 192,715 shares on 01/05/2026 for $6,749,100.06.
Rhea-AI Filing Summary
Mineralys Therapeutics insider transactions: David Rodman reported multiple sales of common stock, including a sale of 192,715 shares on 01/05/2026 for $6,749,100.06. The filing also shows numerous smaller open‑market sales in January–February 2026 and a broker‑assisted cashless exercise of 2,171 shares on 03/09/2026.
Positive
- None.
Negative
- None.
Insights
Large, disclosed insider sales by a named executive over a short period.
The filing lists multiple dispositions by David Rodman, highlighted by a 192,715‑share sale on 01/05/2026 for $6,749,100.06. Transactions appear as routine open‑market sales and a broker‑assisted cashless exercise of 2,171 shares on 03/09/2026.
These entries document past sales; cash‑flow recipients are the selling holder(s). Timing and rationale for the sales are not stated in the excerpt; subsequent filings would be the source for any further detail.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did David Rodman report in the Mineralys (MLYS) Form 144?
How much did the largest disclosed Mineralys sale by Rodman raise?
Does the Form 144 show exercises or only sales for MLYS?
Are the sale dates and amounts for MLYS listed in the filing?
Who received the proceeds from the Mineralys transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.